Our mission is to enhance the survival and quality of life for people living with GIST through patient-powered research, education and empowerment, and global advocacy efforts.

What’s in the Patient Section?

What’s in the Powered Section?

What’s in the Science section?

What’s in the For Life Section?

Real World Evidence In Action

Traditional models for cancer research have resulted in many breakthrough treatments for patients, but it is not enough. The LRG’s approach to research through real world evidence, relies on timely, accurate data from the patient’s perspective, with patient survival as the primary objective.

GIST Collaborative Tissue Bank
GIST Trials Database
The Life Raft Group Patient Registry
SideEQ
Project Surveillance

RECENT LRG DATA

0
Patients in LRG Registry
0%
of Patient Registry members know their mutation
0
Total # of Tissue
0%
of LRG members know their Risk of Recurrence

Update your Patient Registry Information.

Update

Join The Life Raft Group.

Join Our Community

Available GIST clinical trials.

Learn About Trials

Search our database of GIST Specialists.

View Specialists
Dr. Monica Anderson

Dr. Monica Anderson

Diagnosed in 2012 with Adult GIST.

Marc Wasserman

Marc Wasserman

Diagnosed in 2006 with Adult GIST.

Bella Rocco

Bella Rocco

Diagnosed in 2009 with Pediatric
(SDH-Deficient) GIST.

HELP US SAVE LIVES

The Life Raft Group is a community and it is up to all of us to make a difference. There are many ways to help. We always need patient tissue and data in our registry. Volunteering your time or making a monetary donation also helps us drive research forward and save lives.

SHARE YOUR DATA
DONATE TO THE LRG
VOLUNTEER YOUR TIME
CONTRIBUTE YOUR TISSUE
  • LRG Science Thumbnail

First-Line Imatinib More Effective Than Widely Believed – LRG Science

The latest issue of LRG Science is titled, "First-Line Imatinib More Effective Than Widely Believed - LRG Science - Treatment for Resistant GIST - Improved, but Still Very Far to Go." In this issue, the LRG Real World Evidence team analyzes data from our Patient Registry in order to evaluate the efficacy of imatinib as a first-line treatment in GIST. Subscribe to LRG Science by emailing mgarland@liferaftgroup.org with the subject line SUBSCRIBE LRG SCIENCE.

  • LRG News Icon

Priority Review Granted for Ripretinib

By |February 14th, 2020|

Deciphera Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for ripretinib for Priority Review. Ripretinib is an investigational broad-spectrum KIT and PDGFRa inhibitor for the treatment of patients with gastrointestinal stromal tumors (GIST).

  • LRG News Icon

NCI Mentions LRG as Component in Development of Ayvakit

By |February 7th, 2020|

In a new article from the NCI concerning the January 2020 approval of Ayvakit, (produced by Blueprint Medicines) the Life Raft Group is acknowledged in the section, “Capturing the Patient Experience.” We are proud to have played a role in supporting the research involved in bringing a new treatment to market for GIST patients.

Keep up with the latest news, events, and opportunities to help.

Subscribe

To contact The Life Raft Group, please call 973-837-9092

GLOBAL PARTNERS